Anti-CPA6 Rabbit Polyclonal Antibody for WB, IHC-P, ELISA - Q8N4T0

Core Product Specifications and Parameters

Biological Background: CPA6 Function and Localization

• Carboxypeptidase A6 (CPA6, also known as CPAH, ETL5, FEB11) is a secreted, zinc-dependent metallocarboxypeptidase that belongs to the peptidase M14 family.
• It is implicated in the proteolytic processing of neuropeptides; specifically, it may inactivate enkephalins and neurotensin in certain brain regions and can convert angiotensin I to the active angiotensin II. Related references: PMID:18178555
• CPA6 preferentially cleaves C-terminal large hydrophobic amino acids, exhibiting minimal activity toward small residues or histidine. Related references: PMID:20855895
• The gene undergoes alternative splicing and chromosomal rearrangements have been observed; mutations in CPA6 are associated with familial febrile seizures and epilepsy, as indicated by its alias FEB11.
• Subcellularly, CPA6 is directed to the extracellular space and extracellular matrix, consistent with its role as a secreted enzyme.
• Expression is predominantly detected in the hippocampus, nucleus raphe, and cortex, supporting its involvement in neurological functions.
• Post-translational modifications include signal peptide cleavage, zymogen activation by removal of a pro-domain, N-glycosylation, and disulfide bond formation.

Experimental Guidance and Technical Tips

• The immunogen (amino acids 130–437) corresponds to the catalytic domain of human CPA6, suggesting that the antibody may recognize both pro- and active forms, as well as truncated variants; verify performance in relevant sample systems.
• For Western blot (WB), a band around 51 kDa is expected; consider using reducing and non-reducing conditions to assess potential disulfide-mediated dimerization or aggregation.
• In IHC-P, paraffin-embedded tissue sections may require antigen retrieval; optimal staining has been observed in brain tissues (hippocampus, cortex), but validate with appropriate controls.
• This polyclonal antibody may exhibit batch-to-batch variability; it is advisable to titrate the antibody and include blocking with the immunogen or a specific peptide for competition assays.
• For ELISA, the antibody can be used as a capture or detection reagent; cross-reactivity with human, mouse, and rat CPA6 supports multi-species assay development.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides this anti-CPA6 polyclonal antibody as part of its comprehensive IVD raw-material portfolio, supporting neuroscience and epilepsy research. As a one-stop sourcing bridge, we offer validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and rare target sourcing to accelerate your assay development from concept to clinic.